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ARTICLE
Clinical Study
Apatorsen plus docetaxel versus docetaxel alone in platinum-
resistant metastatic urothelial carcinoma (Borealis-2)
Jonathan E. Rosenberg1, Noah M. Hahn2, Meredith M. Regan3, Lillian Werner3, Ajjai Alva4, Saby George5, Joel Picus6, Robert Alter7,
Arjun Balar8, Jean Hoffman-Censits9, Petros Grivas10, Richard Lauer11, Elizabeth A. Guancial12, Christopher Hoimes13, Guru Sonpavde14,
Constantine Albany15, Mark N. Stein16, Tim Breen17, Cindy Jacobs18, Kirsten Anderson18, Joaquim Bellmunt3, Aly-Khan A. Lalani3,
Sumanta Pal19 and Toni K. Choueiri 3
BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27
expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy.
METHODS: Multicentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600mg intravenous followed by
weekly doses) plus docetaxel (75 mg/m2 intravenous every 21 days) (A/D) or docetaxel alone. Overall survival (OS) was the primary
end point with a P value <0.1 (one-sided) being positive. Progression-free survival (PFS), objective response rate (ORR), safety, and
effect of Hsp27 levels on outcomes were secondary end points.
RESULTS: Patients randomised to A/D (n= 99) had improved OS compared to docetaxel alone (n= 101): HR: 0.80, 80% CI:
0.65–0.98, P= 0.0784, median 6.4 vs 5.9 months. PFS and ORR were similar in both arms. A/D had more incidence of sepsis and
urinary tract infections. Patients with baseline Hsp27 levels <5.7 ng/mL had improved OS compared to those with levels ≥5.7 ng/
mL. Patients with a decline or ≤20.5% increase in Hsp27 from baseline beneﬁted more from A/D than those with >20.5% increase.
CONCLUSIONS: A/D met its predeﬁned OS end point in patients with platinum-refractory mUC in this phase II trial. This trial is
hypothesis generating requiring further study before informing practice.
British Journal of Cancer (2018) 118:1434–1441; https://doi.org/10.1038/s41416-018-0087-9
INTRODUCTION
Heat shock proteins (Hsp) are a family of highly conserved
proteins whose expression is induced by cell stressors such as
hyperthermia, oxidative stress, cytotoxic chemotherapy, and
radiation.1 Hsp27 is highly expressed in many cancers and is
associated with poor prognosis.1,2 Hsp27 also stabilises mutated or
inappropriately activated oncoproteins that contribute to the
initiation, growth, and metastasis of human cancers.3–7 While
Hsp27 is expressed in low levels in normal bladder epithelium,8
expression is increased in bladder cancer.9–11
Apatorsen (OGX-427) is an antisense oligonucleotide (ASO)
designed to bind to Hsp27 mRNA, resulting in the inhibition of the
production of Hsp27 protein.12,13 Apatorsen is similar to endo-
genous DNA but contains second-generation ASO chemical
modiﬁcations intended to optimise its pharmacological potency,
pharmacokinetics, and safety proﬁle. In vitro and in vivo evidence
indicates that Hsp27 inhibition leads to inhibition of tumour
growth and sensitisation to cytotoxic chemotherapy,14,15 and a
trial of apatorsen as intravesical therapy for non-muscle invasive
bladder cancer showed promising anticancer activity.16 Phase I
studies of apatorsen as a single agent and in combination with
docetaxel appeared to be well tolerated even at the highest dose
of 1000mg.17
We report the efﬁcacy and safety of apatorsen in combination
with docetaxel compared to docetaxel alone in patients with
metastatic urothelial carcinoma previously treated with platinum-
based chemotherapy. This randomised, controlled phase II trial
with a primary end point of overall survival was designed to
provide a strong rationale for whether to move forward with a
phase III trial in this patient population.
PATIENTS AND METHODS
Study design and participants
This was a randomised, phase II, investigator-sponsored, multi-
centre, open-label trial conducted among academic and
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community sites within the Hoosier Cancer Research Network
(HCRN). Patients with metastatic or locally advanced inoperable
urothelial carcinoma (TNM staging T4b, N2, N3, or M1) previously
treated with platinum-based chemotherapy were enrolled. To be
eligible, patients 18 years or older were required to have
measurable disease, an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1, and estimated life
expectancy of 3 or more months. All patients must have received
at least one prior platinum-based chemotherapy regimen with a
maximum of two regimens. Patients who relapsed within 1 year of
platinum-based perioperative chemotherapy were eligible.
Patients whose tumours contained variant histological features
were eligible if the tumour was not considered a pure histologic
variant; however, patients with any amount of small cell
carcinoma were not eligible. Patients were required to have
adequate organ function (serum creatinine ≤1.5× upper limit of
normal (ULN)), no worse than grade 1 peripheral neuropathy, no
known brain or spinal cord metastases, no active second
malignancy, no cerebrovascular accident, myocardial infarction,
or pulmonary embolus within 3 months of enrollment, and no
prior treatment with docetaxel.
Randomisation
Patients were randomly assigned to apatorsen plus docetaxel or
docetaxel alone in a one-to-one ratio using permuted blocks
within strata. Randomisation was generated using a clinical trial
management system software (OnCore) and patients were
stratiﬁed based on 0 vs 1–3 adverse Bellmunt prognostic factors
(liver metastases, haemoglobin <10 g/dL, ECOG performance
status 1) and time from prior systemic chemotherapy (<3 months
vs ≥3 months).18,19
Procedures
For patients assigned apatorsen plus docetaxel, apatorsen 600mg
was administered intravenously in three separate loading doses
separated by at least one non-treatment day over a 9-day period.
Patients were administered an antihistamine or an H2 antagonist
prior to each of the three loading doses. Following the loading
doses, patients received docetaxel 75 mg/m2 in 21-day cycles and
apatorsen 600mg weekly until disease progression, unacceptable
toxicity, or a maximum of 10 cycles of docetaxel. Patients who
completed 10 cycles or stopped docetaxel for toxicity continued
maintenance apatorsen until disease progression or unacceptable
toxicity related to apatorsen. For patients assigned docetaxel
alone, docetaxel was administered at a dose of 75 mg/m2 every
21 days until disease progression, unacceptable toxicity, or a
maximum of 10 cycles of docetaxel. Dose reductions for docetaxel
(from 75mg/m2 to 60mg/m2 to 45mg/m2) were required for
haematologic toxicity, peripheral sensory neuropathy, or mucosi-
tis. Dose reductions for apatorsen (from 600mg to 500 mg to
400mg) were required for renal toxicity, and dose reductions for
both agents were required for hepatotoxicity.
Study end points
The primary end point was overall survival (OS), deﬁned from
randomisation until death due to any cause, or censored on date
last known alive. Secondary efﬁcacy end points were progression-
free survival (PFS), deﬁned from randomisation to objective
disease progression or death from any cause, whichever occurred
ﬁrst, or censored at date of last disease evaluation without
progression; objective response rate (ORR; complete or partial
response as best overall response) and duration of response,
which were evaluated by RECIST criteria version 1.1. Radiographic
Enrollment
(N = 200)
Randomised 1:1
allocated
Allocated to docetaxel and apatorsen (n = 99)
Follow-up for survival (n = 95) Follow-up for survival (n = 99)
Withdrew or lost to follow-up for survival (n = 2)
1 withdrew consent
1 lost to survival follow-up
99 off treatment
0 still on treatment
Withdrew or lost to follow-up for survival (n = 4)
94 off treatment
3 withdrew consent
1 lost to survival follow-up
Included in analysis (n = 99)
Excluded from analysis (n = 0)
Included in analysis (n = 101)
Excluded from analysis (n = 0)
1 still on treatment
Allocated to docetaxel (n =101)
96 received allocated intervention
5 did not receive allocated intervention
93 received allocated intervention
6 did not receive allocated intervention
Fig. 1 Trial CONSORT ﬂow diagram
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evaluations were performed at baseline with cross-sectional
imaging and repeated every 6 weeks until disease progression.
Patients with bone metastases on baseline bone scan were
required to have imaging every 6 weeks for the ﬁrst 4 cycles and
then every 12 weeks thereafter until disease progression. If any
new clinical signs or symptoms of disease progression developed,
imaging was repeated as clinically indicated. Safety was reported
according to National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE version 4.0) and assessed from
initiation of study treatment until 30 days after last study therapy.
Exploratory objectives included assessing the associations of
baseline and post-treatment serum Hsp27 levels with survival
outcomes. Hsp27 levels were analysed by a central laboratory
using enzyme-linked immunosorbent assay analysis, as has been
previously described.20
Statistical analysis
This phase II study was designed to have 90% power with one-
sided 0.10 signiﬁcance level to detect a 33% reduction in the OS
hazard rate with docetaxel and apatorsen compared with
docetaxel alone [hazard ratio (docetaxel and apatorsen/docetaxel)
= 0.667], assuming an exponential distribution of OS, and median
OS of 6 months on docetaxel alone.21 The speciﬁed phase II error
levels were considered to provide adequate precision of the
hazard ratios (HR) in order to inform the design of a subsequent
phase III trial. The randomised, controlled design speciﬁed one
interim analysis for futility after ~81 deaths and ﬁnal analysis after
162 deaths. The cutoff date for ﬁnal analysis was 10 October 2016.
Patient and clinical characteristics were summarised as numbers
and percentage for categorical variables and median with range
for continuous variables. OS and PFS were compared between the
two treatment assignments using a stratiﬁed log-rank test with a
one-sided α= 0.10. The Kaplan–Meier (KM) method was used to
estimate OS and PFS distributions by treatment arm. Stratiﬁed Cox
proportional hazards (PH) models estimated hazard ratios (HR)
and 80% two-sided conﬁdence intervals, which corresponds to
one-sided α= 0.10, in unadjusted and multivariable models.
Subgroup analyses investigated treatment effects according to
the stratiﬁcation factors, estimating HRs and testing for treatment-
by-subgroup interaction in Cox PH models.
ORR was summarised as numbers and percentage of partici-
pants by treatment assignments with two-sided 80% CI and
compared using Fisher’s exact tests. Median duration of response
was estimated using KM method in patients who achieved partial
or complete response as best overall response, deﬁned from time
objective response was ﬁrst observed until disease progression or
death. A planned stratiﬁed Cox PH model assessed the association
of baseline serum Hsp27 level with OS and to test the treatment-
by-Hsp27 interaction. Baseline serum Hsp27 levels were categor-
ized at the median for assessing the associations with OS, given
that no clinically meaningful cutoff point had been previously
established. Among patients who were alive after cycle 2, the
association of percentage change of Hsp27 level from baseline to
end of cycle 2 with OS (re-deﬁned from end of cycle 2 as landmark
analysis) was investigated similarly.
RESULTS
Patients
Between August 2013 and September 2015, 200 patients were
enrolled at 32 study sites in the United States. Ninety-nine patients
were randomised to docetaxel and apatorsen and 101 patients to
treatment with docetaxel alone. Overall, 194 participants had
complete follow-up for survival and 6 were lost to follow-up or
withdrew consent without survival follow-up. All 200 participants
were included in the intention-to-treat (ITT) analysis population
(Fig. 1). Baseline characteristics were well balanced as shown in
Table 1. Overall, median age of participants was 67 years
(interquartile range, IQR 59–74) and 149 participants (74.5%) were
male. Eighty-four (42.0%) had ECOG performance status of 0 at
screening. In terms of patient stratiﬁcation, 140 (70%) had 1–3
Bellmunt prognostic factors and 87 (43.5%) had time from prior
systemic chemotherapy <3 months.
Therapy administration
Among patients who started docetaxel, a median of two cycles
were received in both groups and among those who received
Table 1. Baseline characteristics
Treatment assignment
Characteristic, n (%) Apatorsen and
docetaxel (n= 99)
Docetaxel
(n= 101)
Age, median years
(range)
68 (43–90) 67 (35–92)
Sex
Male 74 (74.7%) 75 (74.3%)
Female 25 (25.3%) 26 (25.6%)
Race
Caucasian 89 (89.9%) 92 (91.1%)
African American 3 (3%) 4 (4%)
Asian 5 (5.1%) 3 (3%)
Unknown 2 (2%) 2 (2%)
ECOG performance statusa
0 43 (43.4%) 41 (40.6%)
1 56 (56.6%) 59 (58.4%)
Urothelial carcinoma (at study entry)
Metastatic 85 (85.9%) 87 (86.1%)
Locally advanced 6 (6.1%) 10 (9.9%)
Unknown 8 (8.1%) 4 (4%)
Primary surgery
Yes 40 (40.4%) 36 (35.6%)
Prior cisplatin use
Yes 70 (70.7%) 72 (71.3%)
Prior carboplatin use
Yes 38 (38.4%) 41 (40.6%)
Primary disease site(s)
Bladder 64 (64.6%) 72 (71.3%)
Renal pelvis 27 (27.3%) 13 (12.9%)
Ureter 13 (13.1%) 14 (13.9%)
Urethra 7 (7.1%) 9 (8.9%)
Metastatic sites
Liver 28 (28.3%) 25 (24.8%)
Lung 34 (34.3%) 35 (34.7%)
Bone 19 (19.2%) 21 (20.8%)
Lymph nodes 56 (56.6%) 52 (51.5%)
Bellmunt prognostic factorsb
0 27 (27.3%) 32 (31.7%)
1 42 (42.4%) 35 (34.7%)
2 23 (23.2%) 26 (25.7%)
3 7 (7.1%) 7 (6.9%)
Prior paclitaxel use was balanced between both arms (n= 10 arm A and n
= 12 arm B). ECOG Eastern Cooperative Oncology Group. aOne patient in
the docetaxel arm had ECOG performance status of 2. bOne patient in the
docetaxel arm had unknown Bellmunt prognostic factors
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apatorsen, a median of 6 weeks (or doses) of treatment were
received. Seven patients went on to receive maintenance
apatorsen after stopping docetaxel, with additional weeks of
apatorsen reported as: 1, 2, 3, 7, 7, 33, and 61 weeks for these
patients.
Primary end point: overall survival
Median follow-up time for all surviving patients was 21.6 months
(range, <1–35.3 months). At the time of analysis, 163 deaths were
reported, with 77 (77.8%) assigned docetaxel and apatorsen and
86 (85.1%) assigned docetaxel. Patients assigned to docetaxel and
apatorsen had a reduction in hazard of death as compared to
patients assigned docetaxel alone (HR: 0.80; 80% CI: 0.65–0.98,
one-sided P= 0.0784, median OS 6.4 vs 5.9 months). The
estimated 12-month OS was 34.4% and 25.0% among patients
assigned to docetaxel and apatorsen vs docetaxel alone,
respectively (Fig. 2).
Secondary end points and subgroup analysis
Patients assigned to docetaxel and apatorsen had a reduced
hazard of disease progression or death as compared to patients
assigned to docetaxel alone, although the results were not
statistically signiﬁcant (HR: 0.80, 80% CI: 0.64–1.01, one-sided P=
0.1069, median PFS 1.8 vs 1.6 months, estimated 12-month PFS
8.7% vs 3.8%).
One-hundred and forty-ﬁve patients had evaluable disease by
RECIST 1.1 criteria. The ORR was 16.1% (80% CI: 11.5–21.9) for
patients assigned docetaxel and apatorsen vs 10.9% (80% CI:
7.1–16.0) for those assigned docetaxel alone (one-sided P=
0.1531). Median duration of response was 6.2 months and
4.4 months in the docetaxel plus apatorsen and docetaxel alone
responders, respectively.
Subgroup analysis was performed on patients with Bellmunt
prognostic factors 0 vs 1–3 as well as those with time from prior
systemic chemotherapy <3 vs ≥3 months. In participants with 0
risk factors, treatment with docetaxel and apatorsen vs docetaxel
alone resulted in a median OS 14.3 vs 10.9 months (HR: 0.91, 80%
CI: 0.59–1.42), compared to a median OS of 5.6 vs 5.1 months in
those with 1–3 risk factors (HR: 0.77, 80% CI: 0.61–0.97). In
participants with time from prior systemic chemotherapy
≥3 months, median OS was 8.0 vs 6.7 months for patients
assigned docetaxel and apatorsen vs docetaxel alone (HR: 0.89,
80% CI: 0.67–1.18) and in those with time from prior systemic
chemotherapy <3 months, the median OS was 5.9 vs 4.7 months
(HR: 0.71, 80% CI: 0.53–0.96) for patients assigned docetaxel and
apatorsen vs docetaxel, respectively.
There was also no signiﬁcant impact on survival for patients
having primary surgery, compared to those that did not (HR: 0.90;
80% CI: 0.73–1.12, one-sided P= 0.2638).
Safety
Of the 200 participants randomised, 189 (93 assigned docetaxel
plus apatorsen and 96 assigned docetaxel alone) initiated protocol
treatment and were included in the safety population. Overall, 187
(98.9%) patients experienced an adverse event (AE) of any grade.
The most common all-grade AEs were fatigue, anorexia, constipa-
tion, diarrhoea, nausea, anaemia, leukopaenia, and neutropaenia
(Table 2). Among patients assigned to docetaxel and apatorsen, 77
(82.8%) had at least one grade 3–5 AE reported compared with 72
(75.0%) patients assigned to docetaxel alone. Common grade 3–5
AEs, including neutropaenia, leukopaenia, anaemia, and febrile
neutropaenia, were well balanced between both groups. Patients
treated with docetaxel and apatorsen had greater incidence of
sepsis (15.1% vs 8.3%; n= 14 vs 8) and urinary tract infections
(14% vs 7.3%; n= 13 vs 7) compared to those treated with
docetaxel alone. Thirteen percent of patients discontinued
treatment due to unacceptable adverse events (16.2% (n= 16)
assigned docetaxel and apatorsen and 9.9% (n= 10) assigned
docetaxel). Five patients in each arm experienced grade 5 AEs. In
the docetaxel and apatorsen arm, one was possibly drug related
to the treatment combination, and one was possibly drug related
to apatorsen only. One death in each arm was possibly drug
related to docetaxel alone.
Exploratory analyses: serum Hsp27 levels
Of the 200 participants, 161 (80.5%) had a baseline serum Hsp27
level available (80 in arm A and 81 in arm B). Median Hsp27 level
was 5.7 ng/mL. In patients who had a baseline Hsp27 level
<5.7 ng/mL (n= 79), median OS was signiﬁcantly higher com-
pared to those with a baseline level ≥5.7 ng/mL (n= 82) (median
100
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HR: 0.80, 80% CI (0.65, 0.98)
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OS 9.4 vs. 4.7 months, HR: 0.51, 80% CI: 0.41–0.65, one-sided P=
0.0001, estimated 12-month OS 43.6% vs 15.2%) (Fig. 3). Treat-
ment with docetaxel and apatorsen improved survival in both
groups of patients with either baseline Hsp27 level <5.7 ng/mL
(HR: 0.71, 80% CI: 0.50–1.00) or ≥5.7 ng/mL (HR: 0.67, 80% CI:
0.48–0.92; two-sided P= 0.87 for interaction) compared to
docetaxel alone.
A landmark analysis was performed after cycle 2 to evaluate the
change in Hsp27 level from baseline. Eighty patients (40 in each
treatment group) had measurements available at both time points
and median percentage change in serum Hsp27 from baseline to
end of cycle 2 was an increase of 20.5% (range, −76.8 to
+677.8%). In patients with a decrease or ≤20.5% increase of
Hsp27, treatment with docetaxel and apatorsen signiﬁcantly
improved overall survival vs docetaxel alone (HR: 0.29, 80% CI:
0.18–0.48, median OS 12.2 vs 5.1 months) compared to those who
had >20.5% increase in Hsp27 levels (HR: 0.77, 80% CI: 0.46–1.30,
median OS 7.9 vs 6.8 months; two-sided P= 0.0727 for
interaction).
DISCUSSION
The addition of apatorsen to docetaxel chemotherapy met its
predeﬁned end point resulting in improved overall survival
compared to docetaxel alone in patients with metastatic urothelial
carcinoma who are relapsed or refractory after a platinum-
containing regimen. Although the improvement in median overall
survival was 2 weeks, the hazard ratio and Kaplan–Meier curves
show the overall beneﬁt for the addition of apatorsen. However,
these data are hypothesis generating and conﬁrmatory trials are
warranted to further study this targeted agent in patients with
metastatic urothelial carcinoma.
Currently in the United States, single-agent immune checkpoint
blockade with anti-PD-1/PD-L1 antibodies is the standard of care
for patients following progression on platinum-based chemother-
apy,22–24 and vinﬂunine is a cytotoxic approved for this indication
in the European Union.25 While the development of immune
checkpoint blockade has represented a breakthrough for patients
with advanced urothelial carcinoma, the vast majority of patients
fail to respond to single-agent PD-1 or PD-L1 inhibition with
Table 2. Selected adverse events among the safety population initiating assigned treatment
Treatment assignment
Patients given docetaxel and apatorsen (n= 93) Patients given docetaxel (n= 96)
Grades 1–2 Grade 3 Grade 4 Grade 5 Grades 1–2 Grade 3 Grade 4 Grade 5
Fatigue 56 (60%) 7 (7%) 0 0 54 (56%) 12 (12%) 0 0
Diarrhoea 40 (43%) 7 (7%) 0 0 30 (31%) 5 (5%) 0 0
Anaemia 24 (26%) 16 (17%) 0 0 25 (26%) 10 (10%) 2 (2%) 0
Nausea 39 (42%) 2 (2%) 0 0 31 (32%) 3 (3%) 0 0
Anorexia 42 (45%) 0 0 0 29 (30%) 1 (1%) 0 0
Neutropaenia 4 (4%) 14 (15%) 19 (20%) 0 4 (4%) 11 (11%) 18 (19%) 0
Constipation 35 (38%) 2 (2%) 0 0 24 (25%) 1 (1%) 0 0
Dyspnea 22 (24%) 6 (6%) 0 0 26 (27%) 3 (3%) 1 (1%) 0
Leukopaenia 4 (4%) 18 (19%) 9 (10%) 0 4 (4%) 14 (14%) 5 (5%) 0
Alopecia 26 (28%) 0 0 0 26 (27%) 0 0 0
Peripheral neuropathy 27 (29%) 1 (1%) 0 0 22 (23%) 0 0 0
Creatinine increased 28 (30%) 2 (2%) 0 0 11 (11%) 1 (1%) 0 0
Muscle weakness 14 (15%) 4 (4%) 0 0 14 (14%) 4 (4%) 0 0
Oral mucositis 14 (15%) 1 (1%) 0 0 19 (20%) 2 (2%) 0 0
Vomiting 16 (17%) 4 (4%) 0 0 13 (13%) 3 (3%) 0 0
Dysgeusia 17 (18%) 0 0 0 17 (18%) 0 0 0
Hyponatremia 16 (17%) 7 (7%) 0 0 7 (7%) 4 (4%) 0 0
Urinary tract infection 7 (7%) 13 (14%) 0 0 6 (6%) 7 (7%) 0 0
Lymphopaenia 6 (6%) 11 (12%) 0 0 4 (4%) 6 (6%) 1 (1%) 0
Hypertension 7 (7%) 4 (4%) 0 0 5 (5%) 8 (8%) 0 0
Thrombocytopaenia 12 (13%) 0 0 0 10 (10%) 0 0 0
Sepsis 0 3 (3%) 9 (10%) 2 (2%) 0 1 (1%) 7 (7%) 0
Rash (maculopapular) 13 (14%) 0 0 0 8 (8%) 0 0 0
Febrile neutropaenia 0 9 (10%) 1 (1%) 0 2 (2%) 8 (8%) 0 0
Thromboembolic events 6 (6%) 3 (3%) 0 0 2 (2%) 5 (5%) 0 0
Intracranial
haemorrhage
0 0 0 1 (1%) 0 0 0 1 (1%)
Cardiac arrest 0 0 0 0 0 0 0 1 (1%)
Colonic perforation 0 0 0 0 0 0 0 1 (1%)
Hepatic failure 0 0 0 0 0 0 0 1 (1%)
Death NOS 0 0 0 1 (1%) 0 0 0 1 (1%)
Multi-organ failure 0 0 0 1 (1%) 0 0 0 0
Selected grades 1–2 (in at least 10% of patients) and grades 3, 4, and 5 adverse events. NOS not otherwise speciﬁed
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response rates of 15–25%.22–24,26,27 For these patients, there are
no proven life-prolonging treatments, and the outlook remains
quite bleak. Furthermore, efﬁcacy results from phase II trials of
many of these agents, which have led to accelerated FDA approval
status, remain to be rigorously veriﬁed in the phase III setting and,
in some cases, have not been conﬁrmed in the subsequent phase
trial.28 The phase III RANGE study, which evaluated ramucirumab
plus docetaxel in platinum-refractory metastatic urothelial carci-
noma, showed a modest PFS improvement of only 1.3 months
compared to docetaxel plus placebo.29 Due to its gate-keeping
statistical design, the study does not allow for formal testing of
response rate unless OS beneﬁt reaches HR 0.75 (currently
immature). There were limited number of patients receiving
immune checkpoint blockade prior and subgroup analysis did not
show any beneﬁt in patients with visceral metastasis. Therefore,
novel agents that target chemotherapy-resistant urothelial carci-
noma are still desperately needed.
Preclinical and smaller clinical data have shed light on the
rationale for activity and beneﬁt from ASO therapy targeting
Hsp27. Hsp27 is a stress-activated, ATP-independent, cytoprotec-
tive chaperone that is upregulated in cancer and is associated
with treatment resistance. Inhibition of Hsp27 expression in vitro
and in vivo leads to increased sensitivity to cytotoxic chemothera-
pies.14,15 In addition, suppression of Hsp27 may lead to long-term
dormancy in vivo in the absence of chemotherapy though
inhibition of angiogenesis.30 Collectively, these ﬁndings may
provide rationale for outcomes observed on this trial: while the
median difference in overall survival was small, the hazard ratio
suggests a 20% reduction in the risk of death over the course of
the study associated with the combination treatment arm.
The biology of Hsp27 and its targeting by ASO has been shown
to have challenges. Through the interplay of TNF-α and IL-10,
Hsp27 is known to have anti-inﬂammatory effects.31 Further, while
second-generation ASOs have modiﬁcations to allow greater
nuclease resistance and increased binding afﬁnities than their
predecessors, potential toxicities include hybridisation-dependent
toxicities—due to on- or off-target pharmacology—and
hybridisation-independent toxicities due to nonantisense
effects.32 Inhibition of Hsp27 by ASOs, therefore, may result in
tumour suppression at the expense of increased inﬂammation.
Indeed, in our study we noted a slightly higher incidence of sepsis
(15.1% vs 8.3%; n= 14 vs 8) and urinary tract infections (14% vs
7.3%; n= 13 vs 7) in those treated with combination therapy.
These safety signals are generally consistent with those seen in
the Borealis-1 study, which evaluated platinum-based chemother-
apy with or without apatorsen (600 or 1000mg) vs chemotherapy
plus placebo in the ﬁrst-line setting.20 Toxicity was noted to be
higher in the 1000 mg apatorsen arm compared to the 600mg
arm in that study, although the primary end point of improved OS
was not met with either apatorsen dose compared to chemother-
apy alone. In the phase III AFFINITY study of men with metastatic
castration-resistant prostate cancer who progressed after doc-
etaxel, custirsen, an ASO to clusterin, administered with
chemotherapy showed no OS beneﬁt vs chemotherapy alone.33
Our study, however, met its predeﬁned end point and the future
prospect of ASOs in urothelial carcinoma may depend on better
patient selection, for example, with accurate biomarkers.
In our subgroup analysis, patients with lower baseline serum
Hsp27 levels (<5.7 ng/mL) appeared to have better overall survival
than those with higher baseline levels (≥5.7 ng/mL), irrespective of
treatment. Therapy with apatorsen and docetaxel appeared to
beneﬁt both those with lower or higher Hsp27 levels, suggesting
that baseline serum Hsp27 levels may act as a potential
prognostic, but not predictive, biomarker in these patients.
Furthermore, combination treatment with apatorsen and doc-
etaxel appeared to beneﬁt those with either a decline or limited
increase of Hsp27 level ≤20.5% (HR: 0.29, 80% CI: 0.18–0.48) more
so than those with an increase of >20.5% (HR: 0.77, 80% CI:
0.46–1.30) when comparing baseline and post cycle 2 levels. This
ﬁnding may suggest that dynamic changes of Hsp27 levels in
patients could serve as an indicator predicting beneﬁt to
combination treatment. Ultimately, these ﬁndings are simply
hypothesis generating and may be informative for future trial
designs.
These results should be interpreted in the context of study
design. This was a randomised, controlled, comparative trial with
one-sided 0.10 alpha-level test reﬂecting the objective to
determine if the combination provided survival beneﬁt relative
to docetaxel alone. The rationale for this statistical design was that
the addition of apatorsen to docetaxel was not felt to potentially
yield a negative effect compared to docetaxel alone; however, this
does allow for a higher false-positive rate and there is a potential
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for lead time bias with the apatorsen run-in. In the context of
recent phase III results for immunotherapy agents in this space,
our ﬁndings reinforce the importance of OS as a signiﬁcant end
point in well-designed later phase studies when evaluating
potential practice-impacting treatments.28 To be eligible for our
trial, patients must have received at least one prior platinum-
based chemotherapy regimen, and no patient may have received
more than two regimens for metastatic disease. While the current
landscape is evolving for patients who are platinum-ineligible, and
there are new options in the platinum-refractory setting (e.g.,
immunotherapy), this was not part of established treatment
paradigm at the time of our study design. Therefore, the efﬁcacy
of apatorsen in patients having received immunotherapy is not
currently assessed and granular data on subsequent lines of
therapy are not available in this analysis. Furthermore, we only
analysed serum Hsp27 levels at baseline and after cycle 2 as a
potential marker of response to treatment. Evaluating the
expression of Hsp27 measured by immunohistochemistry (IHC)
in tumour tissue, as well as the effect of therapy on peripheral
circulating tumour cells (CTCs), would be meaningful additional
exploratory end points and, while not available in this current
report, are planned future analyses.
In conclusion, the addition of apatorsen to docetaxel che-
motherapy met its predeﬁned survival end point in patients with
refractory metastatic urothelial carcinoma in this phase II trial.
These data are hypothesis generating and would require further
study before informing clinical practice for this targeted therapy in
metastatic urothelial carcinoma.
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